Gapping up
In reaction to strong earnings/guidance:
- EVER +25.1%, NPTN +16.7%, TEN +15%, KPTI +12%, PODD +11.2%, SWAV +9.2%, HIIQ +8.4%, TDG +8.4%, AVTR +7.7%, DISCA +7.2%, TTWO +6.8%, PBI +6.5%, WPX +6.4%, PLUG +6.1%, APPS +6%, SEAS +6%, ZTS +5.7%, IPI +5.6%, ENDP +5.3%, CHK +5.1%, ACB +4.8%, ITRI +4.4%, SHAK +3.6%, OUT +3.6%, MNK +3.4%, KLAC +3.2%, BHC +3.2%, KALA +3.2%, DIOD +2.9%, EPC +2.9%, EMR +2.2%, MIME +1.8%, O +1.7%, REGN +1.5%, VCEL +1.5%, THC +1.4%, USFD +1.4%, STE +1.3%, CXW +1.2%, APLE +1%, ENBL +0.9%, CECE +0.9%, LGIH +0.9%, .
Other news:
- RMTI +8.8% (announces acceptance by FDA of NDA for I.V. TRIFERIC; PDUFA set for March 28)
- NVAX +1.2% (Novavax reaches agreement with FDA on pivotal Phase 3 trial design for NanoFlu )
- CLDR +1.2% (Carl Icahn increases active stake)
Analyst comments:
- CI +2.5% (upgraded to Outperform from Mkt Perform at Bernstein)
- F +2.1% (upgraded to Overweight from Equal-Weight at Morgan Stanley)
- FEYE +1.6% (initiated with a Buy at Nomura)
- XOM +0.4% (upgraded to Hold from Sell at DZ Bank)